# Molecular Imaging of Primary Amyloid Cardiomyopathy

Study · id `cardio:ct-nct02641145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02641145](<https://clinicaltrials.gov/study/NCT02641145>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02641145

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 171 participants.

## Technical summary

Registry record NCT02641145. Non-randomized; no masking; primary purpose diagnostic. Start 2016-04-01 (registry gives no type); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 171 participants (planned count; ClinicalTrials.gov record NCT02641145, source copy `cardio:ctgov-nct02641145-2025-11-14`, retrieved 2026-10-31)
- Start date: 2016-04-01 (registry gives no type) (ClinicalTrials.gov record NCT02641145, source copy `cardio:ctgov-nct02641145-2025-11-14`, retrieved 2026-10-31)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT02641145, source copy `cardio:ctgov-nct02641145-2025-11-14`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT02641145, source copy `cardio:ctgov-nct02641145-2025-11-14`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02641145, source copy `cardio:ctgov-nct02641145-2025-11-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02641145-2025-11-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Molecular Imaging of Primary Amyloid Cardiomyopathy
- Acronym: MICA
- Condition: Amyloidosis, Primary
- Condition: Cardiomyopathy
- Intervention (Radiation): F-18 florbetapir/C-11 acetate PET
- Intervention (Device): MRI
- Intervention (Radiation): N-13 ammonia PET
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: National Institutes of Health (NIH)
- Collaborator class: NIH
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH
- Collaborator: American Heart Association
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: National Institutes of Health (`cardio:nih`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)
- Registry lists this organization as a collaborator: American Heart Association (`core:aha`)

## Provenance

Content hash: 8aec755669cc17e5b3c4b9e9953a996ecad36b5f1d929474825f8c2bd6b1adc2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
